April 9, 2024 News by Andrea Lobo, PhD Mavenclad now OK’d in UK to also treat active relapsing MS patients The prescribing label for Mavenclad (cladribine) in Great Britain has been extended to include the treatment of adults with active relapsing forms of multiple sclerosis (MS), as defined by clinical or imaging features. This decision made the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) the first to…
December 7, 2023 News by Margarida Maia, PhD Quality of life gains with Mavenclad sustained for 2 years: Phase 4 trial Treatment with Mavenclad (cladribine) over two years significantly improved physical and mental health aspects of quality of life in people with highly active relapsing multiple sclerosis (MS), according to a final analysis of data from the Phase 4 CLARIFY-MS study. Mavenclad is an oral medicationĀ approved for people with…
November 13, 2023 News by Steve Bryson, PhD ChariotMS trial of Mavenclad in UK enrolls 100 progressive MS patients ChariotMS, the world’s first clinical trial to test whether Mavenclad (cladribine) can slow the worsening of upper limb function in people with progressive multiple sclerosis (MS), has now enrolled 100 participants. The announcement means the Phase 2 trial (NCT04695080) has reached 50% of its target recruitment goal.
August 7, 2023 News by Andrea Lobo, PhD Mavenclad lowers relapse rates, helps RRMS patients reach NEDA-3 Treatment with Mavenclad (cladribine), an approved short-course oral therapy for relapsing forms of multiple sclerosis (MS), significantly reduced patients’ relapse rates and the development of new lesions while keeping disability stable over two years, according to a real-world study in Kuwait. Among patients who completed the two courses…
July 10, 2023 News by Steve Bryson, PhD Mavenclad found comparable to Gilenya in highly active MS Mavenclad (cladribine) is equally as effective as Gilenya (fingolimod) in reducing relapse rates among multiple sclerosis (MS) patients with highly active disease, according to a new real-world comparison. Disability worsening and the development of new lesions also were similar between the two patient groups ā but…
April 11, 2023 News by Steve Bryson, PhD Mavenclad benefits for MS sustained up to 15 years after last treatment The benefits of Mavenclad (cladribine) were sustained for up to 15 years after its last treatment course in people with relapsing multiple sclerosis (MS), according to real-world data from the CLASSIC-MS study. More than half of those who received the oral therapy in the clinical trials that supported…
April 7, 2023 News by Andrea Lobo, PhD Early treatment with Mavenclad, antibodies eased highly active MS Early treatment with Mavenclad (cladribine) or monoclonal antibodies is more likely to control symptoms in people with highly active multiple sclerosis (MS), a study in Argentina suggests. Highly active disease usually is considered when frequent relapses occur and there is an increasing burden of brain magnetic resonance imaging…
March 13, 2023 News by Andrea Lobo, PhD WHO asked to add 3 MS treatments to its list of ‘essential medicines’ Aiming to promote equitable accessĀ toĀ multiple sclerosis (MS) treatments worldwide, an international MS alliance is asking that threeĀ disease-modifying therapies (DMTs) be added to the World Health Organization’s (WHO) list of essential medicines. Inclusion on the WHO list is considered an important if “initial” step in assuring that helpful treatments…
August 5, 2022 Columns by John Connor Pesky Leukocytes Dash My Hopes of Joining a Trial of Mavenclad for MS In December 2019, I was stopped in my tracks, or rather wheels, as I was about to have my third infusion of Ocrevus (ocrelizumab), the multiple sclerosis disease-modifying therapy (DMT) that Iād been taking every six months for the past year. My neurologist had decided just a few…
July 1, 2022 News by Marisa Wexler, MS Efficacy, Safety of Mavenclad in Real World Similar to That of Trials The safety and efficacy of the approved multiple sclerosis (MS)Ā therapy Mavenclad (cladribine) in a real-world group of patients were similar to what had been demonstrated in clinical trials, a new study reports. Among 243 people with relapsing-remitting multiple sclerosis (RRMS), more than 60% showed no…
February 28, 2022 News by Marisa Wexler, MS #ACTRIMS2022 ā Mavenclad Best at Reducing Relapses: Real-world Data People with multiple sclerosis (MS) who are treated with Mavenclad (cladribine) are less likely to experience a disease relapse than those who are treated with Gilenya (fingolimod), Tecfidera (dimethyl fumarate), or Aubagio (teriflunomide), according to an analysis of real-world data. The findings were presented at the Americas Committee…
February 4, 2022 Columns by John Connor At 64, I’m Surprised to Be Scrambling to Mount a Chariot As usual, Iāve gone for what I hope to be an intriguing headline, because youāve got to grab a reader by any means necessary. If youāve read this far, Iām winning! This saga goes back well over a year, when my neurologist suggested I participate in a clinical trial for…
December 8, 2021 News by Marisa Wexler, MS Report: Tecfidera, Aubagio Preferred RRMS Treatments in Canada Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights. The report was part of SpherixāsĀ RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS…
November 9, 2021 News by Marisa Wexler, MS Ocrevus Still Top Therapy for Progressive MS Forms, Report Finds Ocrevus (ocrelizumab) continues to be the most commonly prescribed therapy for progressive forms of multiple sclerosis (MS), including primary progressive MS (PPMS) and secondary progressive MS (SPMS), according to an analysis from the market intelligence firm Spherix Global Insights. However, other therapies are “gaining traction” among…
October 15, 2021 News by Marta Figueiredo, PhD #ECTRIMS2021 ā Real-world Data Support Mavenclad Benefits in Relapsing MS Editorās note: TheĀ Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13ā15. GoĀ here to see the latest stories from the conference. Mavenclad…
August 16, 2021 Columns by Ed Tobias MS News That Caught My Eye Last Week: Mavenclad, Sativex, Mistreatment, Patient Survey Trial Will Test Mavenclad for Advanced Progressive MS I often think that researchers have forgotten about people whose MS has progressed to an advanced stage. But MS patients who have moved into a wheelchair deserve treatment with a disease-modifying therapy as much as those who are just beginning their…
August 10, 2021 News by Marta Figueiredo, PhD Trial Will Test Mavenclad for Advanced Progressive MS After some delays due to the COVID-19 pandemic, the Phase 2/3 clinical trial evaluating whether Mavenclad (cladribine) can slow hand and arm function worsening in adults with progressive multiple sclerosis (MS) and very limited walking abilities, has recruited its first patient. The study,Ā ChariotMS (NCT04695080), aims to…
July 26, 2021 Columns by Ed Tobias MS News That Caught My Eye Last Week: Mavenclad, Genetic Risk, Fatigue Impact, Multivitamins Skin Reactions āFrequentā With Mavenclad, Real-world Study Finds I regularly see people posting on social media about having a rash or itchy skin, or losing hair while taking Mavenclad. Researchers in this study say these side effects aren’t mentioned in the risk management plans for this disease-modifying therapy. Therefore,…
July 23, 2021 News by Margarida Maia, PhD Skin Reactions ‘Frequent’ With Mavenclad, Real-world Study Finds Skin reactions are common amongĀ relapsing-remitting multiple sclerosis (RRMS) patients being treated with oral Mavenclad (cladribine), affecting about one-third of the people evaluated inĀ a real-world study in Germany. These findings suggest the need for careful clinical surveillance to rapidly diagnose and possibly treat skin problems stemming from Mavenclad’s use,…
June 28, 2021 News by Marisa Wexler, MS Early Use of High-efficacy DMTs Favor Lesser Disability Over Time Long-term disability outcomes tend to be better in people with relapsing-remitting multiple sclerosis (RRMS) who are treated early on with highly effective therapies, a study based on patient registry data indicates. The study, “Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or…
May 17, 2021 News by Marisa Wexler, MS Mavenclad’s Ability to Lower RRMS Relapse Rates May Last Years, Study Says Treatment with Mavenclad (clabridine) reduces the frequency of relapses in people with relapsing-remitting multiple sclerosis (RRMS), with benefits appearing to be evident two years after patients stopped taking the treatment, new data suggest. These findings wereĀ in the study, “Analysis of frequency and severity of relapses…
May 14, 2021 Columns by Ed Tobias Efficacy of Pfizer-BioNTech COVID-19 Vaccine Varies by DMT, Study Finds Are you being treated with a disease-modifying therapy (DMT) and wondering how it might affect the efficacy of an mRNA-based COVID-19 vaccine? If so, a recent study may provide some clarity. The study, published in Therapeutic Advances in Neurological Disorders, looked at 125 MS patients either being treated with…
May 7, 2021 Columns by John Connor Slipping Over the Event Horizon Into SPMS Isn’t it just like me to start my column with a physics analogy that is already confusing? Please stick with me, as all will be revealed. My point is that if a black hole is big enough, you might slip through its event horizon without even noticing. There would…
April 29, 2021 News by Marisa Wexler, MS #AANAM ā Exploring Mavenclad’s Effects on Immune Cells Editorās note: TheĀ Multiple Sclerosis News TodayĀ team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17ā22. GoĀ hereĀ to read stories from the conference. After starting treatment with the multiple sclerosis (MS) therapy Mavenclad (cladribine), some types of immune cells are more affected…
April 27, 2021 News by Forest Ray PhD #AANAM ā Mavenclad, for RRMS, Lowers Long-term Need for Other DMTs Editorās note: TheĀ Multiple Sclerosis News TodayĀ team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17ā22. GoĀ hereĀ to read the latest stories from the conference. A majority of theĀ relapsing-remitting multiple sclerosis (RRMS) patients givenĀ Mavenclad (cladribine) tablets in the CLARITY Phase 3 trial did…
March 18, 2021 News by Margarida Maia, PhD Mavenclad Quickly Reduces MRI Lesions in Early MS, ORACLE-MS Data Show Mavenclad (cladribine) reduces the number and volume of lesions in patients at risk of multiple sclerosis (MS) after a first clinical demyelinating event, a study based on Phase 3Ā trial data found. A demyelinating event occurs when myelin ā the protective coating around nerve fibers ā experiences damage; this…
November 23, 2020 News by Marisa Wexler, MS ChariotMS to Test Mavenclad in SPMS, PPMS Patients With Little Ability to Walk An upcoming Phase 2 clinical trial, called ChariotMS, will test whether Mavenclad (cladribine) can slow a worsening of hand and arm function in people with progressive multiple sclerosis (MS) and very limited walking abilities. Patients reliant on wheelchairs or aids to walk even short distances generally have…
October 28, 2020 News by Marisa Wexler, MS Mavenclad for RRMS Now Available Through Seven Provincial Public Drugs Plans in Canada Eligible people with relapsing-remitting multiple sclerosis (RRMS) now have access toĀ MavencladĀ (cladribine) through seven provincial public drug plans in Canada, including the RĆ©gie de l’assurance maladie du QuĆ©bec (RAMQ) and the Ontario Drug Benefit Exceptional Access Program. The oral treatment now is available through public drug programs…
September 10, 2020 News by Joana Carvalho, PhD #MSVirtual2020 – New Safety, Efficacy Data on Mavenclad, Rebif and Evobrutinib on Way EMD Serono will present new data from programs assessing the efficacy and safety of Mavenclad (cladribine) andĀ Rebif (interferon beta-1a), as well as investigative evobrutinibĀ in treatingĀ relapsing forms of multiple sclerosis (MS) at the MSVirtual2020 meeting. FindingsĀ are part of 54 abstracts being presented by EMD Serono,…
August 31, 2020 Columns by Ed Tobias MS News That Caught My Eye Last Week: Paramagnetic Lesions, Mavenclad, Relapses in Children, Ocrevus and Rituximab Paramagnetic Rim Lesions Showing Promise as Diagnostic Marker of MS About a year ago, researchers at the U.S. National Institutes of Health reported that the presence of chronic active lesions in the brain may provide a clue as to how quickly multiple sclerosis symptoms will progress. They called them…